Is Codexis, Inc. (CDXS) a Buy, Sell, or Hold?
Codexis, Inc.
NASDAQ:CDXS
$2.13 USD
-$0.12 (-5.33%)
- Volume
- 926.31K
- Average Volume
- 1.02M
- Market Capitalization
- $193.61M
- P/E Ratio
- -5.82
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $3.87
- Year Low
- $0.96
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.36
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Alison Moore |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CDXS |
| CUSIP | 192005106 |
| CIK | 0001200375 |
| Web | https://www.codexis.com |
| Phone | 650 421 8100 |
| Currency | USD |
| Employees | 146 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.69 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.36 |
| Quick Ratio | 5.23 |
| Cash Ratio | 2.49 |
Sales & Book Value
| Annual Sales | $70.39M |
| Price / Sales | 2.48 |
| Cash Flow | -0.24 |
| Price / Cash Flow | -8.75 |
| Price / Book | 4.47 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -57.40% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.5 |
| Trailing P/E Ratio | -5.82 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-43.97M |
| Net Margin | -40.96% |
| Pretax Margin | -40.87% |
| Return on Equity | -68.09% |
| Return on Assets | -24.73% |
Financials Score
| AltmanZ Score | -4.81 |
| Piotroski Score | 4.00 |
| Working Capital | 64.8M |
| Total Assets | 129.37M |
| Ebit | -30.63M |
| Market Cap | 204.52M |
| Total Liabilities | 86.14M |
Poll Results
About Codexis, Inc. (NASDAQ:CDXS) Stock
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhanc ... ing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
2026-05-08 14:41:23
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-07 20:11:38
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis Reports First Quarter 2026 Financial Results
2026-05-07 16:05:00
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
2026-04-30 11:06:27
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis to share RNA manufacturing advances at TIDES USA
2026-04-29 09:00:00
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.
Frequently Asked Questions
-
What is the current Codexis, Inc. (CDXS) stock price?
-
Codexis, Inc.(NASDAQ:CDXS) stock price is $2.13 in the last trading session. During the trading session, CDXS stock reached the peak price of $3.87 while $0.96 was the lowest point it dropped to. The percentage change in CDXS stock occurred in the recent session was --5.33% while the dollar amount for the price change in CDXS stock was -$-0.12.
-
CDXS's industry and sector of operation?
-
The NASDAQ listed CDXS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CDXS?
-
John Schiffhauer | Senior Vice President of Intellectual Property
Karen Frechou-Armijo | Senior Vice President & Head of Human Resources
Senator Byron L. Dorgan | Consultant
Britton Jimenez | Senior Vice President of Sales & Marketing
Alison Moore | President, Chief Executive Officer & Director -
How many employees does CDXS have?
-
Number of CDXS employees currently stands at 146. CDXS operates from 200 Penobscot Drive, Redwood City, CA 94063, US.
-
Link for CDXS official website?
-
Official Website of CDXS is: https://www.codexis.com
-
How do I contact CDXS?
-
CDXS could be contacted at phone #650 421 8100 and can also be accessed through its website. CDXS operates from 200 Penobscot Drive, Redwood City, CA 94063, US.
-
How many shares of CDXS are traded daily?
-
The average number of CDXS shares traded daily for last 3 months was 1.02M.
-
What is the market cap of CDXS currently?
-
The market value of CDXS currently stands at $193.61M with its latest stock price at $2.13